We are pulmonary hypertension professionals united in our vision for a world without pulmonary vascular disease. We believe we can achieve this together, and we won’t stop until we do.
Drug Discovery and Development Symposium 2025
Full scientific programme is live! With the theme of ‘Inclusive and sustainable drug development for PAH’, the programme is divided into 6 sessions: new standards of care, disease modification, diversity and inclusion, global aspects of drug development and availability, innovations in trial design, and novel drug & device therapies.
We're delighted to announce PVRI 2026 will be taking place in the vibrant and historic city of Dublin. Held in the Dublin Royal Convention Centre (28 - 31 January), we can't wait to see you there! Stay tuned for more details...
Whether you’re a pulmonary hypertension specialist, a pharmaceutical or industry colleague, a regulator, a patient, or a caregiver, joining our growing global family means you share our vision to reduce the global burden of pulmonary vascular disease.
This year’s symposium will bring together regulatory, industry, and academic bodies in the field, offering a unique platform for in-depth discussions, knowledge exchange, and collaboration on the latest drug advancements in PH. Registration is open.
Cellular communication network 2 (CCN2) is a secreted matricellular protein associated with pulmonary arterial hypertension (PAH) but has not been studied relative to PAH severity, outcomes, or right ventricle (RV) structure and function in a large human cohort and preclinical animal model.
Pulmonary arterial hypertension (PAH) is a disease that can eventually progress to right ventricular failure. Heart rate variability (HRV), including standard deviation of R-to-R intervals (SDNN), has been associated with increased mortality across different populations. The purpose of this study was to examine the association between HRV and disease severity in PAH.
Congenital heart disease (CHD) occurs at increased prevalence at high altitude, but there may be a paradoxical later onset of the development of Eisenmenger syndrome. We hypothesized that congenital heart disease patients at high altitude are protected from an early onset of irreversible pulmonary hypertension.
We’re pleased to share that the Pulmonary Hypertension Global Patient Survey (PHGPS) - a key project of the IDDI Patient Engagement & Empowerment (PE&E) Workstream - is now a stand-alone Task Force.
We are delighted to invite our members to submit suggestions for the next PVRI Digital series, which is scheduled to start in September 2025 and will run for 18 months.
The PVRI 2025 Annual Congress was hosted in the vibrant city of Rio de Janeiro at the Windsor Convention & Expo Centre. Esteemed experts, healthcare professionals, and researchers from around the globe gathered in this iconic city to share groundbreaking insights, foster collaborations, and advance our collective mission towards conquering PVD.
Rubin Tuder, a trailblazer in the field of pulmonary vascular biology and a driving force in PH research, has been honoured with the PVRI Lifetime Achievement Award for 2025. This prestigious Award is given annually at the PVRI Annual Congress to a senior PH investigator or clinician for their exceptional and outstanding contributions to the field of pulmonary vascular disease and to PVRI. This recognition celebrates his unparalleled contributions to science, mentorship, and the global PH community.
